Moreover, randomized controlled trials are warranted to investigate whether novel classes of glucose-lowering agents such as glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors can improve myocardial health and clinical outcomes in patients with severe AS-T2D. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.